About Concord Biotech Limited
Data last updated: 05 January 2026
Concord Biotech Limited is a public limited company based in Ahmedabad, Gujarat, India. It specialises in chemical products, a part of the broader chemicals sector. Incorporated on 23 November 1984, the company has been in operation for over 42 years.
Registered with ROC Ahmedabad under CIN L24230GJ1984PLC007440. Listed.
Capital: an authorised share capital of ₹11 Cr and a paid-up capital of ₹10.46 Cr. Formerly known as Servomed Pharmaceuticals Private Limited and Servomed Pharmaceuticals Limited. It is led by directors including Arvind Motilal Agarwal and Rajiv Ambrish Agarwal.
Last AGM: 09 September 2025. Financial statements filed for year ended 31 March 2025. Office: 1482 – 86 Trasad Road Dholka, Ahmedabad, Gujarat, India – 387810.
As per the financials filed for FY 2023, the company reported a revenue of ₹888.48 Cr, a growth of 20.66% compared to the previous year.
The company has a workforce of approximately 1,516 employees as per the latest available data.
The company is associated with 1 brand - Concord Biotech. As per MCA filings, the company has open charges of ₹45 Cr and satisfied charges of ₹154.77 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website concordbiotech.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered Address1482 – 86 Trasad Road Dholka, Ahmedabad, Gujarat, India – 387810
-
IndustryChemicals, Chemical Products, Medicinal Chemical & Botanical Products, Pharmaceuticals
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Concord Biotech Limited
Concord Biotech Limited has undergone 2 name changes throughout its history. The company was previously known as Servomed Pharmaceuticals Private Limited, and Servomed Pharmaceuticals Limited. The current legal name is Concord Biotech Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Concord Biotech Limited | Current |
| Servomed Pharmaceuticals Private Limited | Previous |
| Servomed Pharmaceuticals Limited | Previous |
CIN History of Concord Biotech Limited
Concord Biotech Limited has one previous CIN (Corporate Identification Number): U24230GJ1984PLC007440. The current CIN is L24230GJ1984PLC007440, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230GJ1984PLC007440 | Current |
| U24230GJ1984PLC007440 | Previous |
Associated Brands with Concord Biotech Limited
Concord Biotech Limited operates one associated brand: Concord Biotech. These brands represent Concord Biotech Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| APIs and enzymes are manufactured through fermentation by the CDMO. | concordbiotech.com |
Competitors & Alternatives of Concord Biotech Limited
Brands and companies operating in the same space as Concord Biotech Limited include BDR Pharmaceuticals Internationals, Almac Group, Indoco Remedies and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
BDR Pharmaceuticals Internationals
|
APIs and finished products are developed and manufactured. | Mumbai, India, India | 2003 |
Almac Group
|
Integrated CDMO services for biopharma R&D and manufacturing are offered. | Craigavon, United Kingdom, United Kingdom | 2001 |
Indoco Remedies
|
APIs manufacturing and formulation services are provided in therapeutic segments. | Mumbai, India, India | 1947 |
Pharmaceutics International
|
Pharmaceutical dosage forms are manufactured by this CDMO. | Hunt Valley, United States, United States | 1994 |
Aurobindo Pharma
|
Generic biocatalytic solutions are provided for pharmaceutical applications. | Hyderabad, India, India | 1986 |
Seqens
|
Contract manufacturing services for small molecules and peptides are provided. | Ecully, France, France | 2003 |
Asymchem
|
APIs and peptides are developed and manufactured by Asymchem. | Morrisville, United States, United States | 1995 |
Biophore
|
Niche generic pharmaceuticals are developed and manufactured for industry needs. | Hyderabad, India, India | 2007 |
Continuus Pharma
|
MIT-Novartis spinoff offering continuous manufacturing solutions to remove the proverbial wall between API and FDF manufacturing in small molecule development | Woburn, United States, United States | 2012 |
Business Activity of Concord Biotech Limited
Concord Biotech Limited operates primarily in the manufacturing sector. The company has 1 registered business activity segment, reflecting its diverse operational portfolio.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| ********* | Manufacturing | ********* | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Concord Biotech Limited
Concord Biotech Limited is audited by B S R & Co. LLP (ICAI peer reviewed, certificate valid till 2028-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| B S R & Co. LLP (ICAI peer reviewed, certificate valid till 2028-07-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Concord Biotech Limited
Concord Biotech Limited is currently managed by 10 directors, with 25 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Arvind Motilal Agarwal
Also directs:
Concord Biotech Limited, Klj Plasticizers Limited.
|
Director | 24 May 2022 | 4 Years 1 Months | Current |
| Rajiv Ambrish Agarwal | Director | 30 Jun 2008 | 18 Years 0 Months | Current |
|
Bharti Khanna
Also directs:
Concord Biotech Limited, Amarant Lifesciences Private Limited
|
Director | 31 Jan 2017 | 9 Years 5 Months | Current |
|
Amitabh Gajendra Thakore
Also directs:
Concord Biotech Limited, Biomix Network Limited
|
Director | 31 Jan 2017 | 9 Years 5 Months | Current |
|
Chakravarthy Sriraman Mandayam
Also directs:
Concord Biotech Limited
|
Director | 14 Jun 2022 | 4 Years 0 Months | Current |
|
Ravi Kapoor
Also directs:
Amity Consultants Llp, Yan Advisory Services Llp, Sanghi Industries Limited and 5 more
|
Director | 15 Dec 2003 | 22 Years 6 Months | Current |
Financials of Concord Biotech Limited FY 2026 filings available
Concord Biotech Limited reported revenue of ₹1,054.89 Cr (down 12.1% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Revenue from Operations | ₹1,054.89 Cr | ₹1,200.09 Cr | ₹1,016.94 Cr |
| Other Income | ₹52.36 Cr | ₹44.45 Cr | ₹33.78 Cr |
| Total Income | ₹1,107.25 Cr | ₹1,244.53 Cr | ₹1,050.72 Cr |
| Cost of Materials Consumed | ₹254.35 Cr | ₹264.31 Cr | ₹184.54 Cr |
| Purchases of Stock-in-Trade | ₹62.61 Cr | ₹55.99 Cr | ₹56.74 Cr |
| Changes in Inventories | -₹71.28 Cr | -₹14.79 Cr | -₹12.08 Cr |
| Employee Benefit Expense | ₹176.9 Cr | ₹138.93 Cr | ₹123.05 Cr |
| Finance Costs | ₹28.32 Lakh | ₹52.93 Lakh | ₹2.55 Cr |
| Depreciation & Amortisation | ₹74.46 Cr | ₹54.37 Cr | ₹53.59 Cr |
| Other Expenses | ₹264.91 Cr | ₹249.31 Cr | ₹233.14 Cr |
| Total Expenses | ₹762.23 Cr | ₹748.66 Cr | ₹641.53 Cr |
| Profit Before Exceptional Items & Tax | ₹345.01 Cr | ₹495.88 Cr | ₹409.19 Cr |
| Exceptional Items | -₹3.28 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹341.74 Cr | ₹495.88 Cr | ₹409.19 Cr |
| Total Tax Expense | ₹85.42 Cr | ₹122.91 Cr | ₹104.46 Cr |
| Net Profit | ₹259.23 Cr | ₹371.64 Cr | ₹308.1 Cr |
| attributable to Owners | ₹260.91 Cr | ₹371.64 Cr | ₹308.1 Cr |
| attributable to NCI | -₹1.68 Cr | ₹0 | - |
| Other Comprehensive Income | ₹55.24 Cr | ₹5.97 Cr | -₹73,000 |
| Total Comprehensive Income | ₹314.47 Cr | ₹377.61 Cr | ₹308.1 Cr |
| EBITDA (computed) | ₹419.76 Cr | ₹550.78 Cr | ₹465.34 Cr |
| Basic EPS | ₹24.78 | ₹35.52 | ₹29.45 |
| Diluted EPS | ₹24.78 | ₹35.52 | ₹29.45 |
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Total Assets | ₹2,234.73 Cr | ₹2,034.25 Cr | ₹1,700.71 Cr |
| Non-current Assets | ₹984.62 Cr | ₹899.01 Cr | ₹804.48 Cr |
| Current Assets | ₹1,250.11 Cr | ₹1,135.24 Cr | ₹896.23 Cr |
| Property, Plant & Equipment | ₹785.72 Cr | ₹791.81 Cr | ₹571.73 Cr |
| Inventories | ₹326.36 Cr | ₹239.67 Cr | ₹207.95 Cr |
| Trade Receivables | ₹460.2 Cr | ₹521.65 Cr | ₹349.61 Cr |
| Cash & Equivalents | ₹12.19 Cr | ₹90.45 Lakh | ₹15.14 Cr |
| Equity (Net Worth) | ₹2,015.14 Cr | ₹1,812.72 Cr | ₹1,526.65 Cr |
| Equity Share Capital | ₹10.46 Cr | ₹10.46 Cr | ₹10.46 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹0 | ₹38.11 Lakh | ₹6.23 Cr |
| Total Debt (computed) | ₹0 | ₹38.11 Lakh | ₹6.23 Cr |
| Current Liabilities | ₹169.08 Cr | ₹184.06 Cr | ₹142.16 Cr |
| Total Liabilities | ₹219.59 Cr | ₹221.53 Cr | ₹174.06 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Operating Cash Flow | ₹266.88 Cr | ₹244.52 Cr | ₹265.47 Cr |
| Investing Cash Flow | -₹142.72 Cr | -₹159.99 Cr | -₹154.61 Cr |
| Financing Cash Flow | -₹112.88 Cr | -₹98.77 Cr | -₹99.21 Cr |
| Capital Expenditure | ₹95.15 Cr | ₹111.17 Cr | ₹85.69 Cr |
| Free Cash Flow (computed) | ₹171.73 Cr | ₹133.34 Cr | ₹179.78 Cr |
| Dividends Paid | ₹111.94 Cr | ₹91.54 Cr | ₹71.45 Cr |
| Net Change in Cash | ₹11.28 Cr | -₹14.24 Cr | ₹11.64 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹326.08 Cr | ₹277.77 Cr | ₹247.06 Cr | ₹203.99 Cr | ₹429.88 Cr | ₹244.22 Cr | ₹310.18 Cr | ₹215.8 Cr | ₹318.97 Cr | ₹240.8 Cr | ₹262.35 Cr | ₹194.83 Cr |
| Other Income | ₹15.35 Cr | ₹9.98 Cr | ₹13.35 Cr | ₹13.68 Cr | ₹9.38 Cr | ₹14.73 Cr | ₹10.03 Cr | ₹10.31 Cr | ₹10.81 Cr | ₹8.19 Cr | ₹8.13 Cr | ₹6.65 Cr |
| Total Income | ₹341.43 Cr | ₹287.74 Cr | ₹260.41 Cr | ₹217.67 Cr | ₹439.27 Cr | ₹258.95 Cr | ₹320.21 Cr | ₹226.11 Cr | ₹329.78 Cr | ₹248.98 Cr | ₹270.47 Cr | ₹201.48 Cr |
| Cost of Materials Consumed | ₹70.54 Cr | ₹66.59 Cr | ₹57.3 Cr | ₹59.91 Cr | ₹80.27 Cr | ₹60.96 Cr | ₹68.05 Cr | ₹55.03 Cr | ₹55.67 Cr | ₹47.39 Cr | ₹42 Cr | ₹39.48 Cr |
| Purchases of Stock-in-Trade | ₹15.67 Cr | ₹20.44 Cr | ₹13.65 Cr | ₹12.85 Cr | ₹10.32 Cr | ₹12.19 Cr | ₹21.7 Cr | ₹11.78 Cr | ₹11.45 Cr | ₹23.22 Cr | ₹10.48 Cr | ₹11.6 Cr |
| Changes in Inventories | -₹39.62 Lakh | -₹21.3 Cr | -₹21.93 Cr | -₹27.65 Cr | ₹37.91 Cr | -₹20.75 Cr | -₹13.44 Cr | -₹18.51 Cr | ₹21.73 Cr | -₹23.52 Cr | ₹39.24 Lakh | -₹10.67 Cr |
| Employee Benefit Expense | ₹47.77 Cr | ₹46.78 Cr | ₹44.46 Cr | ₹37.9 Cr | ₹38.97 Cr | ₹34.64 Cr | ₹33.66 Cr | ₹31.66 Cr | ₹33.96 Cr | ₹30.67 Cr | ₹30.17 Cr | ₹28.25 Cr |
| Finance Costs | ₹8.4 Lakh | ₹8.15 Lakh | ₹5.91 Lakh | ₹5.86 Lakh | ₹9.55 Lakh | ₹9.74 Lakh | ₹9.56 Lakh | ₹24.08 Lakh | ₹46.28 Lakh | ₹49.53 Lakh | ₹84.06 Lakh | ₹75.32 Lakh |
| Depreciation & Amortisation | ₹19.54 Cr | ₹18.75 Cr | ₹18.39 Cr | ₹17.78 Cr | ₹14.62 Cr | ₹13.26 Cr | ₹13.31 Cr | ₹13.18 Cr | ₹13.72 Cr | ₹13.54 Cr | ₹13.3 Cr | ₹13.04 Cr |
| Other Expenses | ₹73.96 Cr | ₹66.27 Cr | ₹65.09 Cr | ₹59.59 Cr | ₹72 Cr | ₹59.23 Cr | ₹63.52 Cr | ₹54.56 Cr | ₹61.88 Cr | ₹57.11 Cr | ₹60.12 Cr | ₹54.02 Cr |
| Total Expenses | ₹227.18 Cr | ₹197.61 Cr | ₹177.02 Cr | ₹160.43 Cr | ₹254.17 Cr | ₹159.63 Cr | ₹186.91 Cr | ₹147.94 Cr | ₹198.86 Cr | ₹148.9 Cr | ₹157.29 Cr | ₹136.47 Cr |
| Profit Before Exceptional Items & Tax | ₹114.25 Cr | ₹90.13 Cr | ₹83.39 Cr | ₹57.24 Cr | ₹185.09 Cr | ₹99.32 Cr | ₹133.29 Cr | ₹78.17 Cr | ₹130.92 Cr | ₹100.08 Cr | ₹113.18 Cr | ₹65.01 Cr |
| Exceptional Items | ₹0 | -₹3.28 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹114.25 Cr | ₹86.85 Cr | ₹83.39 Cr | ₹57.24 Cr | ₹185.09 Cr | ₹99.32 Cr | ₹133.29 Cr | ₹78.17 Cr | ₹130.92 Cr | ₹100.08 Cr | ₹113.18 Cr | ₹65.01 Cr |
| Total Tax Expense | ₹25.61 Cr | ₹22.51 Cr | ₹22.62 Cr | ₹14.67 Cr | ₹43.16 Cr | ₹25.23 Cr | ₹34.59 Cr | ₹19.93 Cr | ₹33.7 Cr | ₹25.53 Cr | ₹28.68 Cr | ₹16.54 Cr |
| Net Profit | ₹88.47 Cr | ₹63.64 Cr | ₹63.06 Cr | ₹44.06 Cr | ₹140.39 Cr | ₹75.92 Cr | ₹95.74 Cr | ₹59.59 Cr | ₹95.02 Cr | ₹77.57 Cr | ₹81.02 Cr | ₹54.49 Cr |
| attributable to Owners | ₹88.79 Cr | ₹64.48 Cr | ₹63.58 Cr | ₹44.06 Cr | ₹140.39 Cr | ₹75.92 Cr | ₹0 | ₹59.59 Cr | ₹95.02 Cr | ₹77.57 Cr | ₹81.02 Cr | ₹54.49 Cr |
| attributable to NCI | -₹32.35 Lakh | -₹83.51 Lakh | -₹51.81 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | ₹13.26 Cr | ₹22.95 Cr | ₹21.85 Cr | -₹2.82 Cr | ₹7.48 Cr | -₹1.45 Cr | -₹23.03 Lakh | ₹16.93 Lakh | ₹39.63 Lakh | -₹64.87 Lakh | ₹32.31 Lakh | -₹7.79 Lakh |
| Total Comprehensive Income | ₹101.73 Cr | ₹86.59 Cr | ₹84.91 Cr | ₹41.24 Cr | ₹147.87 Cr | ₹74.47 Cr | ₹95.51 Cr | ₹59.76 Cr | ₹95.41 Cr | ₹76.92 Cr | ₹81.34 Cr | ₹54.42 Cr |
| EBITDA (computed) | ₹133.88 Cr | ₹108.96 Cr | ₹101.84 Cr | ₹75.07 Cr | ₹199.81 Cr | ₹112.68 Cr | ₹146.7 Cr | ₹91.59 Cr | ₹145.1 Cr | ₹114.12 Cr | ₹127.32 Cr | ₹78.81 Cr |
| Basic EPS | ₹8.46 | ₹6.08 | ₹6.03 | ₹4.21 | ₹13.42 | ₹7.26 | ₹9.15 | ₹5.70 | ₹9.08 | ₹7.41 | ₹7.74 | ₹5.21 |
| Diluted EPS | ₹8.46 | ₹6.08 | ₹6.03 | ₹4.21 | ₹13.42 | ₹7.26 | ₹9.15 | ₹5.70 | ₹9.08 | ₹7.41 | ₹7.74 | ₹5.21 |
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Revenue from Operations | ₹1,055.07 Cr | ₹1,200.09 Cr | ₹1,016.94 Cr |
| Other Income | ₹52.73 Cr | ₹44.45 Cr | ₹33.78 Cr |
| Total Income | ₹1,107.8 Cr | ₹1,244.53 Cr | ₹1,050.72 Cr |
| Cost of Materials Consumed | ₹254.35 Cr | ₹264.31 Cr | ₹184.54 Cr |
| Purchases of Stock-in-Trade | ₹62.23 Cr | ₹55.99 Cr | ₹56.74 Cr |
| Changes in Inventories | -₹70.61 Cr | -₹14.79 Cr | -₹12.08 Cr |
| Employee Benefit Expense | ₹170.19 Cr | ₹138.93 Cr | ₹123.05 Cr |
| Finance Costs | ₹23.4 Lakh | ₹52.93 Lakh | ₹2.55 Cr |
| Depreciation & Amortisation | ₹74.33 Cr | ₹54.37 Cr | ₹53.59 Cr |
| Other Expenses | ₹262.39 Cr | ₹249.31 Cr | ₹233.14 Cr |
| Total Expenses | ₹753.09 Cr | ₹748.66 Cr | ₹641.53 Cr |
| Profit Before Exceptional Items & Tax | ₹354.71 Cr | ₹495.88 Cr | ₹409.19 Cr |
| Exceptional Items | -₹3.28 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹351.43 Cr | ₹495.88 Cr | ₹409.19 Cr |
| Total Tax Expense | ₹88.17 Cr | ₹122.91 Cr | ₹104.46 Cr |
| Net Profit | ₹263.27 Cr | ₹372.96 Cr | ₹304.73 Cr |
| Other Comprehensive Income | ₹55.78 Cr | ₹5.97 Cr | -₹73,000 |
| Total Comprehensive Income | ₹319.04 Cr | ₹378.93 Cr | ₹304.72 Cr |
| EBITDA (computed) | ₹429.27 Cr | ₹550.78 Cr | ₹465.34 Cr |
| Basic EPS | ₹25.17 | ₹35.65 | ₹29.13 |
| Diluted EPS | ₹25.17 | ₹35.65 | ₹29.13 |
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Total Assets | ₹2,236.54 Cr | ₹2,034.18 Cr | ₹1,699.32 Cr |
| Non-current Assets | ₹991.32 Cr | ₹898.94 Cr | ₹803.08 Cr |
| Current Assets | ₹1,245.22 Cr | ₹1,135.24 Cr | ₹896.23 Cr |
| Property, Plant & Equipment | ₹785.63 Cr | ₹791.81 Cr | ₹571.73 Cr |
| Inventories | ₹325.69 Cr | ₹239.67 Cr | ₹207.95 Cr |
| Trade Receivables | ₹460.6 Cr | ₹521.65 Cr | ₹349.61 Cr |
| Cash & Equivalents | ₹7.89 Cr | ₹90.45 Lakh | ₹15.14 Cr |
| Equity (Net Worth) | ₹2,019.75 Cr | ₹1,812.65 Cr | ₹1,525.25 Cr |
| Equity Share Capital | ₹10.46 Cr | ₹10.46 Cr | ₹10.46 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹0 | ₹38.11 Lakh | ₹6.23 Cr |
| Total Debt (computed) | ₹0 | ₹38.11 Lakh | ₹6.23 Cr |
| Current Liabilities | ₹167.24 Cr | ₹184.06 Cr | ₹142.16 Cr |
| Total Liabilities | ₹216.79 Cr | ₹221.53 Cr | ₹174.06 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Operating Cash Flow | ₹263.78 Cr | ₹244.52 Cr | ₹265.47 Cr |
| Investing Cash Flow | -₹142.28 Cr | -₹159.99 Cr | -₹154.61 Cr |
| Financing Cash Flow | -₹114.51 Cr | -₹98.77 Cr | -₹99.21 Cr |
| Capital Expenditure | ₹95.04 Cr | ₹111.17 Cr | ₹85.69 Cr |
| Free Cash Flow (computed) | ₹168.74 Cr | ₹133.34 Cr | ₹179.78 Cr |
| Dividends Paid | ₹111.94 Cr | ₹91.54 Cr | ₹71.45 Cr |
| Net Change in Cash | ₹6.98 Cr | -₹14.24 Cr | ₹11.64 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹325.89 Cr | ₹278.13 Cr | ₹247.06 Cr | ₹203.99 Cr | ₹429.88 Cr | ₹244.22 Cr | ₹310.18 Cr | ₹215.8 Cr | ₹318.97 Cr | ₹240.8 Cr | ₹262.35 Cr | ₹194.83 Cr |
| Other Income | ₹15.54 Cr | ₹10.08 Cr | ₹13.43 Cr | ₹13.68 Cr | ₹9.38 Cr | ₹14.73 Cr | ₹10.03 Cr | ₹10.31 Cr | ₹10.81 Cr | ₹8.19 Cr | ₹8.13 Cr | ₹6.65 Cr |
| Total Income | ₹341.43 Cr | ₹288.22 Cr | ₹260.49 Cr | ₹217.67 Cr | ₹439.27 Cr | ₹258.95 Cr | ₹320.21 Cr | ₹226.11 Cr | ₹329.78 Cr | ₹248.98 Cr | ₹270.47 Cr | ₹201.48 Cr |
| Cost of Materials Consumed | ₹70.54 Cr | ₹66.59 Cr | ₹57.3 Cr | ₹59.91 Cr | ₹80.27 Cr | ₹60.96 Cr | ₹68.05 Cr | ₹55.03 Cr | ₹55.67 Cr | ₹47.39 Cr | ₹42 Cr | ₹39.48 Cr |
| Purchases of Stock-in-Trade | ₹15.67 Cr | ₹20.07 Cr | ₹13.65 Cr | ₹12.85 Cr | ₹10.32 Cr | ₹12.19 Cr | ₹21.7 Cr | ₹11.78 Cr | ₹11.45 Cr | ₹23.22 Cr | ₹10.48 Cr | ₹11.6 Cr |
| Changes in Inventories | -₹53.57 Lakh | -₹20.5 Cr | -₹21.93 Cr | -₹27.65 Cr | ₹37.91 Cr | -₹20.75 Cr | -₹13.44 Cr | -₹18.51 Cr | ₹21.73 Cr | -₹23.52 Cr | ₹39.24 Lakh | -₹10.67 Cr |
| Employee Benefit Expense | ₹45.02 Cr | ₹44.09 Cr | ₹43.18 Cr | ₹37.9 Cr | ₹38.97 Cr | ₹34.64 Cr | ₹33.66 Cr | ₹31.66 Cr | ₹33.96 Cr | ₹30.67 Cr | ₹30.17 Cr | ₹28.25 Cr |
| Finance Costs | ₹5.84 Lakh | ₹5.84 Lakh | ₹5.86 Lakh | ₹5.86 Lakh | ₹9.55 Lakh | ₹9.74 Lakh | ₹9.56 Lakh | ₹24.08 Lakh | ₹46.28 Lakh | ₹49.53 Lakh | ₹84.06 Lakh | ₹75.32 Lakh |
| Depreciation & Amortisation | ₹19.49 Cr | ₹18.67 Cr | ₹18.39 Cr | ₹17.78 Cr | ₹14.62 Cr | ₹13.26 Cr | ₹13.31 Cr | ₹13.18 Cr | ₹13.72 Cr | ₹13.54 Cr | ₹13.3 Cr | ₹13.04 Cr |
| Other Expenses | ₹72.82 Cr | ₹65.66 Cr | ₹64.32 Cr | ₹59.59 Cr | ₹72 Cr | ₹59.23 Cr | ₹63.52 Cr | ₹54.56 Cr | ₹61.88 Cr | ₹57.11 Cr | ₹60.12 Cr | ₹54.02 Cr |
| Total Expenses | ₹223.06 Cr | ₹194.64 Cr | ₹174.97 Cr | ₹160.43 Cr | ₹254.17 Cr | ₹159.63 Cr | ₹186.91 Cr | ₹147.94 Cr | ₹198.86 Cr | ₹148.9 Cr | ₹157.29 Cr | ₹136.47 Cr |
| Profit Before Exceptional Items & Tax | ₹118.38 Cr | ₹93.57 Cr | ₹85.52 Cr | ₹57.24 Cr | ₹185.09 Cr | ₹99.32 Cr | ₹133.29 Cr | ₹78.17 Cr | ₹130.92 Cr | ₹100.08 Cr | ₹113.18 Cr | ₹65.01 Cr |
| Exceptional Items | ₹0 | -₹3.28 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹118.38 Cr | ₹90.3 Cr | ₹85.52 Cr | ₹57.24 Cr | ₹185.09 Cr | ₹99.32 Cr | ₹133.29 Cr | ₹78.17 Cr | ₹130.92 Cr | ₹100.08 Cr | ₹113.18 Cr | ₹65.01 Cr |
| Total Tax Expense | ₹28.36 Cr | ₹22.51 Cr | ₹22.62 Cr | ₹14.67 Cr | ₹43.16 Cr | ₹25.23 Cr | ₹34.59 Cr | ₹19.93 Cr | ₹33.7 Cr | ₹25.53 Cr | ₹28.68 Cr | ₹16.54 Cr |
| Net Profit | ₹90.02 Cr | ₹67.78 Cr | ₹62.9 Cr | ₹42.57 Cr | ₹141.94 Cr | ₹74.09 Cr | ₹98.7 Cr | ₹58.24 Cr | ₹97.21 Cr | ₹74.55 Cr | ₹84.49 Cr | ₹48.47 Cr |
| Other Comprehensive Income | ₹13.61 Cr | ₹23.08 Cr | ₹21.91 Cr | -₹2.82 Cr | ₹7.48 Cr | -₹1.45 Cr | -₹23.03 Lakh | ₹16.93 Lakh | ₹39.63 Lakh | -₹64.87 Lakh | ₹32.31 Lakh | -₹7.79 Lakh |
| Total Comprehensive Income | ₹103.64 Cr | ₹90.86 Cr | ₹84.8 Cr | ₹39.75 Cr | ₹149.42 Cr | ₹72.64 Cr | ₹98.47 Cr | ₹58.41 Cr | ₹97.61 Cr | ₹73.9 Cr | ₹84.82 Cr | ₹48.39 Cr |
| EBITDA (computed) | ₹137.92 Cr | ₹112.3 Cr | ₹103.97 Cr | ₹75.07 Cr | ₹199.81 Cr | ₹112.68 Cr | ₹146.7 Cr | ₹91.59 Cr | ₹145.1 Cr | ₹114.12 Cr | ₹127.32 Cr | ₹78.81 Cr |
| Basic EPS | ₹8.60 | ₹6.48 | ₹6.01 | ₹4.07 | ₹13.57 | ₹7.08 | ₹9.43 | ₹5.57 | ₹9.29 | ₹7.13 | ₹8.08 | ₹4.63 |
| Diluted EPS | ₹8.60 | ₹6.48 | ₹6.01 | ₹4.07 | ₹13.57 | ₹7.08 | ₹9.43 | ₹5.57 | ₹9.29 | ₹7.13 | ₹8.08 | ₹4.63 |
Shareholding Pattern of Concord Biotech Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 44.08%, foreign institutional investors hold 7.80%, domestic institutional investors hold 9.22%, retail and other public shareholders hold 38.90% of Concord Biotech Limited. The company had 82,249 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% |
| Public | 55.92% | 55.92% | 55.92% | 55.92% | 55.92% | 55.92% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | 44.08% | 44.08% | 44.08% |
| Public | 55.92% | 55.92% | 55.92% |
| Promoter change (YoY, %pts) | +0.00 | +0.00 | - |
Board & Governance of Concord Biotech Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Concord Biotech Limited has 9 directors - 5 independent and 2 executive. The board is chaired by SUDHIR JAIRAM VAID.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| SUDHIR JAIRAM VAID | Executive Director · MD · Chairperson | 2000-05-10 | 1 |
| ANKUR VAID | Executive Director · CEO-MD | 2009-12-04 | 1 |
| RAVI KAPOOR | Non-Executive - Non Independent Director | 2003-12-15 | 2 |
| RAJIV AMBRISH AGARWAL | Non-Executive - Non Independent Director | 2008-06-30 | 2 |
| BHARTI KHANNA | Non-Executive - Independent Director | 2017-01-31 | 1 |
| AMITABH GAJENDRA THAKORE | Non-Executive - Independent Director | 2017-01-31 | 1 |
| JAYARAM EASWARAN | Non-Executive - Independent Director | 2022-06-14 | 1 |
| ARVIND MOTILAL AGARWAL | Non-Executive - Independent Director | 2022-05-24 | 1 |
| CHAKRAVARTHY SRIRAMAN MANDAYAM | Non-Executive - Independent Director | 2022-06-14 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | AMITABH GAJENDRA THAKORE (Chairperson), JAYARAM EASWARAN, ARVIND MOTILAL AGARWAL |
| Nomination and remuneration committee | AMITABH GAJENDRA THAKORE (Chairperson), BHARTI KHANNA, CHAKRAVARTHY SRIRAMAN MANDAYAM |
| Stakeholders Relationship Committee | RAJIV AMBRISH AGARWAL (Chairperson), JAYARAM EASWARAN, RAVI KAPOOR |
| Risk Management Committee | ANKUR VAID (Chairperson), RAVI KAPOOR, AMITABH GAJENDRA THAKORE |
| Corporate Social Responsibility Committee | ANKUR VAID (Chairperson), ARVIND MOTILAL AGARWAL, CHAKRAVARTHY SRIRAMAN MANDAYAM |
Charges & Borrowings of Concord Biotech Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Jan 2003 | Axis Bank Limited | ₹45 Cr | Open |
| 17 Oct 2019 | State Bank of India | ₹110 Cr | Satisfied |
| 11 Aug 2015 | Citi Bank N.A. | ₹30.82 Cr | Satisfied |
| 09 Dec 2014 | Citi Bank N.A. | ₹10 Cr | Satisfied |
| 23 Jan 2012 | Citibank N. A. | ₹3.7 Cr | Satisfied |
Total charge records: 6 View all charges
Employees and EPFO Compliance at Concord Biotech Limited
Concord Biotech Limited has a workforce of 1,516 employees as of Apr 14, 2025.
Employee Count & EPFO Data of Concord Biotech Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Concord Biotech Limited
GSTIN & GST Filing Data of Concord Biotech Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Concord Biotech Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Concord Biotech Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Concord Biotech Limited
MSME Payment Delays by Concord Biotech Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Concord Biotech Limited
Subsidiaries & Group Companies of Concord Biotech Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Concord Biotech Limited with ownership details.
MCA Filings & Documents of Concord Biotech Limited
MCA Filings & Documents of Concord Biotech Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Concord Biotech Limited
Recent News on Concord Biotech Limited
Frequently Asked Questions about Concord Biotech Limited
Concord Biotech Limited is an active public limited company in the chemicals sector based in Ahmedabad, Gujarat, India. It was incorporated on 23 November 1984 (42+ years old) and is registered under CIN L24230GJ1984PLC007440. The company has 1,516 employees.
Concord Biotech Limited reported revenue of ₹888.48 Cr for FY 2023 (up 20.66% YoY).
The current directors of Concord Biotech Limited are:
The primary industry of Concord Biotech Limited is chemicals. The company specifically operates in chemical products. The company is currently active in this sector.
Yes, Concord Biotech Limited is a listed company.
Concord Biotech Limited can be reached at the registered office: 1482 – 86 Trasad Road Dholka, Ahmedabad, Gujarat, India – 387810, or through the website concordbiotech.com.